Pratteln, Switzerland, April 23, 2021 -- Santhera Pharmaceuticals (SIX: 
SANN) will announce its audited 2020 results on Thursday, April 29, 
2021, at 07:00 CEST and will host a conference call at 14:00 CEST. 
 
   Publication of the 2020 financial results and the 2020 Annual Report on 
April 29 (instead of April 27 as previously stated) will allow the 
Company to consider the results of the ongoing Exchange Offer for its 
CHF 60 million 5% Convertible Bonds for which the additional acceptance 
period is expected to end on April 27, 2021, 17:00 CEST. 
 
   CEO Dario Eklund and CFO Andrew Smith will discuss the 2020 financial 
results and recent corporate developments in the conference call at 
14:00 CEST / 13:00 BST / 08:00 EDT the same day. Participants are 
invited to call one of the following numbers 10-15 minutes before the 
conference call starts (no dial-in code is required): 
 
   Europe:        +41 58 310 50 00 
 
   UK:        +44 207 107 06 13 
 
   USA:        +1 631 570 56 13 
 
   About Santhera 
 
   Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical 
company focused on the development and commercialization of innovative 
medicines for rare neuromuscular and pulmonary diseases with high unmet 
medical need. Santhera has an exclusive license for all indications 
worldwide to vamorolone, a first-in-class dissociative steroid with 
novel mode of action, currently investigated in a pivotal study in 
patients with DMD as an alternative to standard corticosteroids. The 
clinical stage pipeline also includes lonodelestat (POL6014) to treat 
cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well 
as an exploratory gene therapy approach targeting congenital muscular 
dystrophies. Santhera out-licensed ex-North American rights to its first 
approved product, Raxone(R) (idebenone), for the treatment of Leber's 
hereditary optic neuropathy (LHON) to Chiesi Group. For further 
information, please visit www.santhera.com. 
 
   Raxone(R) is a trademark of Santhera Pharmaceuticals. 
 
   For further information please contact: 
 
   public-relations@santhera.com 
https://www.globenewswire.com/Tracker?data=shyq9TZNnJ9ZpjBHBIHo374_cklYT95QL2qP9VAaymP5ppYMGe3wgJbDaQxTnVe9-HtGWGliHdlH8_L9uyH5qTYFs_QUDMytfoYY9OIqO4wHHtL-3_bq1mnxBdZoVV-J 
or 
 
   Eva Kalias, Head External Communications 
 
   Phone: +41 79 875 27 80 
 
   eva.kalias@santhera.com 
 
   Disclaimer / Forward-looking statements 
 
   This communication does not constitute an offer or invitation to 
subscribe for or purchase any securities of Santhera Pharmaceuticals 
Holding AG. This publication may contain certain forward-looking 
statements concerning the Company and its business. Such statements 
involve certain risks, uncertainties and other factors which could cause 
the actual results, financial condition, performance or achievements of 
the Company to be materially different from those expressed or implied 
by such statements. Readers should therefore not place undue reliance on 
these statements, particularly not in connection with any contract or 
investment decision. The Company disclaims any obligation to update 
these forward-looking statements. 
 
   # # # 
 
 
 
   Attachment 
 
 
   -- 2021 04 23_FY2020 date_e_final 
      https://ml-eu.globenewswire.com/Resource/Download/151b007a-92c6-40dc-ac84-522e56a97ba2

(END) Dow Jones Newswires

April 23, 2021 12:05 ET (16:05 GMT)